Ensysce Biosciences, Inc. (ENSC)
Oxford Ledge is still expanding full research coverage of ENSC. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Ensysce develops abuse-resistant opioid drugs using enzyme-activated prodrug technology to address pain treatment while preventing drug misuse.
SEC filings
- 8-K Delisting / transfer of listing 2026-05-22
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-15
- 8-K Entry into material agreement; 3.02; Other material event; Financial statements and exhibits 2026-04-08
- 8-K Departure/election of directors or officers; Financial statements and exhibits 2026-04-03
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for ENSC. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open ENSC in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.